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Abstract: Pyrazolo[4,3-b]indole derivatives have been designed as novel CK2 inhibitor compounds 
based on the binding mode analysis of a previously reported phenylpyrazole-type CK2 inhibitor. A 
series of pyrazolo[4,3-b]indoles and related dihydropyrazolo[4,3-b]indoles were efficiently prepared 
from simple starting materials using a gold-catalysed three-component annulation reaction as a key 
step. Several of the newly synthesized compounds displayed high levels of inhibitory activity, 
indicating that the pyrazolo[4,3-b]indole core represents a promising scaffold for the development of 
potent CK2 inhibitors. 
 
Introduction 
The protein kinase CK2 (previously known as casein kinase II) is a ubiquitous, essential and 
highly pleiotropic serine/threonine specific kinase with hundreds of endogenous substrates that are 
implicated in a wide variety of different cellular functions.1 CK2 typically forms tetrameric 
complexes consisting of two catalytic α subunits (i.e. α or α') and two regulatory β subunits in a 
variety of different combinations.2 The CK2α' subtype is exclusively expressed in the brain and testis, 
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whereas the CK2α subtype has been reported to be ubiquitously expressed.3 A significant body of 
evidence is available within the literature to support the idea that CK2 behaves in multifunctional 
capacity in a number of cellular events contributing to the progression of cancer, making it a 
potential target for cancer treatment.4 Although many ATP-competitive and ATP non-competitive 
CK2 inhibitors have already been reported in the literature,5 the benzonaphthyridine derivative CX-
4945 (1) is the only one of these inhibitors to have reached clinical trials for the treatment of cancer 
(Figure 1).5g,5h 
In our initial efforts to develop novel CK2 inhibitors, we performed a series of structure–
activity relationship studies6a and crystallographic analyses7 of pyrazine-based CK2 inhibitors 26b,c 
(Figure 1). These studies revealed that these inhibitors 2 bind to the ATP-binding site with a planar 
horseshoe-shaped conformation and that the nitrogen atom at the 4-positon of the pyrazine ring and 
the (pyrrol-3-yl)acetic acid moiety were necessary for the binding affinities. Furthermore, the virtual 
screening of a compound library using the structure of the CK2α–2b complex, led to the 
identification of a novel CK2 inhibitor lead compound 3a, which consisted of a phenylpyrazole 
scaffold (Figure 1).8 Binding mode analysis suggested that inhibitor 3 could tightly bind to the ATP-
binding region through a series of favourable interactions, whereas the other tautomer 3', in which 
the NH and N positions on the pyrazole ring had be swapped around, could give rise to unfavourable 
electrostatic repulsions with the CK2α (Figure 2). Based on this structural information, it was 
envisaged that the inhibitory activity of the lead compound 3a could be improved by controlling the 
tautomerization process and pushing it towards the favoured structure. With this in mind, we 
designed and synthesized a series of benzo[g]indazole derivatives 4 (Figure 1)9 as novel CK2 
inhibitor compounds. The compounds themselves could be regarded as a conformationally restricted 
analogue of the phenylpyrazole 3. It was anticipated that restricting the rotatable bond in this way 
would provide the preferred planar conformation and lead to a reduction in the entropic loss 
encountered during the binding to CK2α. Furthermore, it was envisaged that the desired tautomer of 
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the pyrazole moiety would be formed preferentially because of the presence of the fused benzene 
ring (Figure 3).10 Indeed, the synthesized benzo[g]indazole derivatives 4a [IC50 = 0.040 µM (CK2α) 
and 0.042 µM (CK2α')] and 4b [IC50 = 0.089 µM (CK2α) and 0.067 µM (CK2α')] exhibited higher 
levels of inhibitory activity towards CK2 than the phenylpyrazole 3a [IC50 = 0.14 µM (CK2α) and 
0.063 µM (CK2α')] (Figure 1). In the present work, we have designed and synthesized a series of 
pyrazolo[4,3-b]indole derivatives 5 (Figure 3) as a new class of CK2 inhibitor compounds in which 
the phenylpyrazole moiety was bridged with a nitrogen atom. Based on the same discussion provided 
for the development of the benzo[g]indazole-type inhibitors 4, enhanced levels of inhibitory activity 
were also expected for the pyrazolo[4,3-b]indoles 5. 
Several methods have been described in the literature for the synthesis of pyrazoloindoles 
according to linear synthetic strategies.11 To the best of our knowledge, however, there have been no 
reports describing the synthesis of pyrazoloindoles based on multiple component reactions 
(MCRs).12 MCRs provide a divergent approach to functionalised pyrazoloindoles from simple 
starting materials. We have recently developed a novel gold-catalysed three-component annulation 
reaction of alkynes, hydrazines and aldehydes/ketones for the direct synthesis of polysubstituted 
dihydropyrazoles (Scheme 1).13 The mechanism of this reaction involves the formation of the 
propargyl hydrazine intermediate via the Mannich-type coupling of alkynes with N,N’-disubstituted 
hydrazines and aldehydes/ketones, followed by intramolecular hydroamination. It was envisaged that 
the pyrazolo[4,3-b]indole-type inhibitor compounds 5 could be efficiently synthesized using this 
gold-catalysed three-component annulation reaction. Herein, we report our synthetic studies towards 
the pyrazolo[4,3-b]indole derivatives 5 and their subsequent evaluation as CK2 inhibitors. 
 
Results and discussion 
Our initial efforts were focused on designing a strategy for the construction of pyrazolo[4,3-
b]indole scaffold via a diversity-oriented synthetic route (Scheme 2). The multi-substituted 
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pyrazolo[4,3-b]indoles 11 could be directed from their dihydropyrazolo[4,3-b]indole congeners 10 
via an oxidative aromatization reaction. The dihydropyrazolo[4,3-b]indoles 10 themselves could in 
principle be accessed by the intramolecular C-H amination of the corresponding dihydropyrazoles 9 
substituted with a phenylazide moiety. It is important to point out at this stage, however, that this 
transformation represented an unprecedented process14 during the design of our synthetic strategy. It 
was anticipated that the dihydropyrazoles 9 could be synthesized by the gold-catalysed three-
component annulation of the ethynylbenzene derivatives 6 bearing an azide group at their ortho-
positions with a variety of different aldehydes and disubstituted hydrazines. 
The gold-catalysed three-component annulation was initially investigated using 1-azido-2-
ethynylbenzene (6a), isobutyraldehyde (7a) and hydrazine derivatives 8a bearing a 4-methoxybenzyl 
(PMB) group as model substrates (Scheme 3). Under the standard reaction conditions [i.e. 3 mol % 
of IPrAuCl/AgOTf in 1,2-dichloroethane (1,2-DCE)] developed during a previously reported 
optimization process,13 the Mannich-type coupling and cyclization reactions proceeded smoothly to 
afford the dihydropyrazole 9a in 73% yield.15 A number of transition metal complexes and Lewis 
acids have been reported to promote C-N bond formation reactions from aryl azides.14 Of the various 
catalysts reported, ruthenium(III) chloride hydrate (RuCl3·nH2O)14e,14f was found to facilitate the 
intramolecular C-H amination reaction to provide the desired dihydropyrazolo[4,3-b]indole 10a in 
moderate yield (62%). Subsequent treatment of 10a with ceric ammonium nitrate (CAN) facilitated 
the cleavage of PMB protecting group and the aromatization of the dihydropyrazole ring to give the 
pyrazolo[4,3-b]indole 11a in high yield (87%). 
Having established the standard protocol to access the desired scaffold, we intended to 
determine its scope and limitations using other ethynylbenzenes, hydrazines, and aldehydes (or 
ketones). Thus, we proceeded to examine the synthesis of multi-substituted dihydropyrazolo[4,3-
b]indoles 10 (and/or pyrazolo[4,3-b]indoles 11) via the three-component annulation reaction 
followed by an intramolecular C-H amination (Table 1). The introduction of electron-withdrawing 
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and electron-donating groups to the para-position of the phenyl ring of the ethynylbenzene unit was 
well tolerated (Table 1, entries 2 and 3). Considering the further application of this synthetic strategy 
to the synthesis of the CK2 inhibitor compounds 5, which contain a carboxy group, ethyl 3-azido-4-
ethynylbenzoate 6b was used as the ethynylbenzene component throughout the remainder of the 
investigation. The use of hydrazines bearing tert-butoxycarbonyl (Boc) and benzyl (Bn) groups was 
also successful (Table 1, entry 4). When other aliphatic and aromatic aldehydes were tested, 
modifications to the reaction conditions were required, with silver 
bis(trifluoromethanesulphonyl)amide (AgNTf2) being used as the silver salt instead of AgOTf to 
effectively promote the three-component annulation reactions (Table 1, entries 5−10). When p-
anisaldehyde was used as the aldehyde component, the efficiency of the three-component annulation 
was significantly diminished, with the desired product 9i being isolated in low yield (31%, Table 1, 
entry 9). It is noteworthy that the intramolecular C-H amination of the dihydropyrazole 9g prepared 
from benzaldehyde gave a mixture of dihydropyrazolo[4,3-b]indole 10g and its aromatized product 
11b (Table 1, entry 7). Particularly for the case of dihydropyrazole 9i prepared from p-anisaldehyde, 
pyrazolo[4,3-b]indole 11c was isolated as the single product (Table 1, entry 9). As the use of the 
ketone, cyclohexanone instead of an aldehyde was well tolerated under the reaction conditions of the 
three-component annulation, and afforded the dihydropyrazole 9j in good yield (Table 1, entry 10). 
The intramolecular C-H amination of 9j in the presence of the RuCl3·nH2O catalyst failed, whereas 
the application of traditional thermal decomposition conditions14j to 9j gave the desired 
dihydropyrazolo[4,3-b]indole 10i in moderate yield (Table 1, entry 10). Disappointingly, the three-
component annulation using paraformaldehyde provided none of the desired product 9k, and resulted 
instead in the formation of a complex mixture (Table 1, entry 11).  
For the synthesis of dihydropyrazole 9k, the decision was taken to adopt a step-wise synthetic 
procedure (Scheme 4) because of difficulties encountered during the attempted synthesis of this 
compound under the three-component annulation conditions. The Sonogashira coupling reaction of 
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the aryl iodide derivative 12 with the propargyl hydrazine derivative 13 afforded the cyclization 
precursor 14. Subsequent heating of 14 in the presence of a catalytic amount of IPrAuCl/AgOTf in 
1,2-DCE facilitated the necessary 5-endo-dig cyclization process to furnish the desired 
dihydropyrazole 9k in good yield (74%). Under the thermal decomposition conditions, 9k was 
successfully converted to the dihydropyrazolo[4,3-b]indole 10j in modest yield (43%).  
With a verity of different dihydropyrazolo[4,3-b]indole derivatives in hand, we proceeded 
with the preparation of the pyrazolo[4,3-b]indole-type CK2 inhibitor compounds 5a−g using further 
functional group transformations (Scheme 5). The N-substituted dihydropyrazolo[4,3-b]indole 
derivatives 15a−d were readily obtained via the N-alkylation or N-arylation reactions of the 
dihydropyrazolo[4,3-b]indole derivatives 10b, 10g and 10j. Subsequent treatment of 10b, 10g, 10j 
and 15a−d with CAN affected the required oxidative aromatization reactions to give the 
pyrazolo[4,3-b]indoles 11b and 11d−i. For the final step in the synthesis, the methyl carbamate and 
ester protecting groups were removed to yield the desired compounds 5a−g. 
We then investigated the in vitro inhibitory activities of the synthesized derivatives toward 
CK2α and CK2α' (Table 2). The analogues 5b and 5f bearing an isopropyl group on their pyrazole 
ring (R1 = i-Pr) showed no inhibition against CK2 at 1µM. In contrast, the benzene-substituted 
analogues 5c and 5g (R1 = Ph) exhibited relatively high levels of inhibitory activity. For the 3-
unsubstituted derivatives 5a, 5d and 5e (R1 = H), the presence of some degree of substitution on the 
nitrogen atom of the indole moiety (R2) was found to be crucial to the high binding affinities. The 
introduction of a Bn group on the nitrogen atom (R2 = Bn) led to a reduction in the inhibitory activity, 
whereas the introduction of a 4-nitrophenyl group at the same position resulted in a 10-fold increase 
in the potency. Of all of the compounds synthesised, compounds 5c and 5e displayed almost 
equipotent inhibitory activities to the lead compound 3a and benzo[g]indazole 4b. The introduction 
of an aromatic ring at the R1 or R2 position led to enhanced binding affinities, perhaps because it 
could form hydrophobic interactions with the surrounding amino acid residues of CK2α.16 
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Considering the loss of the amino group from the pyrazole ring of these compounds, which would 
otherwise have formed a favourable hydrogen bonding interaction with the carbonyl oxygen of the 
Val116 residue (Figure 2), the pyrazolo[4,3-b]indole core represents a promising scaffold for the 
development of potent CK2 inhibitors.  
 
Conclusion 
In conclusion, we have designed a series of pyrazolo[4,3-b]indole derivatives as novel CK2 
inhibitor compounds on the basis of our previous studies on a phenylpyrazole-based CK2 inhibitor. 
Diversity-oriented synthesis of the desired pyrazolo[4,3-b]indoles and related dihydropyrazolo[4,3-
b]indoles was achieved by the application of our gold-catalysed three-component annulation reaction. 
Evaluation of the CK2 inhibitory activities of the resulting compounds led to the identification of 




Melting points were measured by a hot stage melting point apparatus (uncorrected). 1H NMR 
spectra were recorded using a JEOL ECA-500 spectrometer and chemical shifts are reported in δ 
(ppm) relative to TMS as internal standard. 13C NMR spectra were recorded using a JEOL ECA-500 
spectrometer and referenced to the residual solvent signal. 1H NMR spectra are tabulated as follows: 
chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br s = 
broad singlet), coupling constant(s) and number of protons. Exact mass (HRMS) spectra were 
recorded on a JMS-HX/HX 110A mass spectrometer. Infrared (IR) spectra were obtained on a 
JASCO FT/IR-4100 FT-IR spectrometer with JASCO ATR PRO410-S. The purity of the compounds 
5a−g was determined as > 95% by HPLC (method A: Cosmosil 5C18-ARII column, 250 mm × 4.6 
mm; water/acetonitrile containing 0.1% TFA; linear gradient from 90:10 to 70:30 over 30 min; flow 
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rate of 1 cm3/min; UV detector at 220 nm or method B: Cosmosil 5C18-ARII column, 250 mm × 4.6 
mm; water/acetonitrile containing 0.1% TFA; linear gradient from 70:30 to 50:50 over 30 min; flow 
rate of 1 cm3/min; UV detector at 220 nm). Compounds 8a9 and 8b13 were prepared according to the 
literature. 
 
Representative procedure for gold-catalysed three-component annulation of 6a–c with 7 
and 8a,b: synthesis of methyl 5-(2-azidophenyl)-3-isopropyl-2-(4-methoxybenzyl)-2,3-dihydro-
1H-pyrazole-1-carboxylate (9a). Under argon atmosphere, the mixture of 6a (72 mg, 0.5 mmol), 
hydrazine 8a (158 mg, 0.75 mmol), isobutyraldehyde 7a (0.068 cm3, 0.75 mmol), IPrAuCl (9.3 mg, 
0.015 mmol) and AgOTf (3.9 mg, 0.015 mmol) in 1,2-dichloroethane (2.5 cm3) was stirred at 50 °C 
for 4 h. After being cooled to room temperature, the mixture was filtered through Celite and the 
filtrate was concentrated in vacuo. The residue was chromatographed on silica gel (hexane/EtOAc = 
5/1) to afford the title compound 9a (149 mg, 73%) as a colourless oil: IR (neat): νmax/cm-1 2125 (N3), 
1708 (C=O); δH (500 MHz, CDCl3) 0.75−0.77 (6H, m), 1.51−1.58 (1H, m), 3.35 (1H, dd, J 5.7, 2.9 
Hz), 3.59 (3H, s), 3.77 (1H, d, J 12.0 Hz), 3.80 (3H, s), 4.09 (1H, d, J 12.0 Hz), 5.42 (1H, d, J 2.9 
Hz), 6.86 (2H, d, J 8.6 Hz), 7.10−7.13 (1H, m), 7.17−7.18 (1H, m), 7.32−7.36 (2H, m), 7.38 (2H, d, 
J 8.6 Hz); δC (125 MHz, CDCl3) 18.0, 18.2, 32.8, 52.6, 55.2, 61.6, 73.6, 112.8, 113.3 (2C), 118.3, 
124.3, 124.7, 129.0, 129.3, 130.2, 131.5 (2C), 137.2, 137.7, 155.0, 159.0; HRMS (FAB+) Calcd for 
C22H26N5O3 [M+H]+: 408.2036, found: 408.2030. 
 
Representative procedure for ruthenium-catalysed intramolecular C-H amination of 9a–i: 
synthesis of methyl 3-isopropyl-2-(4-methoxybenzyl)-1,2,3,4-tetrahydropyrazolo[4,3-b]indole-1-
carboxylate (10a). Under argon atmosphere, the mixture of 9a (122 mg, 0.3 mmol) and RuCl3·nH2O 
(3.9 mg, 0.015 mmol) in 1,2-dimethoxyethane (3 cm3) was stirred at 80 °C for 4 h. After being 
cooled to room temperature, the mixture was filtered through Celite and the filtrate was concentrated 
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in vacuo. The residue was chromatographed on silica gel (hexane/EtOAc = 3/1) to afford the title 
compound 10a (71 mg, 62%) as a colourless oil: IR (neat): νmax/cm-1 1693 (C=O); δH (500 MHz, 
CDCl3) 0.70−0.75 (6H, m), 1.68−1.74 (1H, m), 3.79−3.83 (5H, m), 3.87 (3H, s), 4.22 (1H, d, J 12.0 
Hz), 6.84 (2H, d, J 8.6 Hz), 7.12−7.17 (2H, m), 7.29−7.31 (1H, m), 7.34 (2H, d, J 8.6 Hz), 7.83−7.86 
(2H, m); δC (125 MHz, CDCl3) 17.7, 18.4, 33.2, 52.9, 55.2, 62.4, 69.9, 111.9, 113.4 (2C), 117.2, 
119.6, 120.3, 121.8, 123.8, 128.7, 129.7, 131.4 (2C), 140.2, 154.4, 159.1; HRMS (FAB+) Calcd for 
C22H26N3O3 [M+H]+: 380.1974, found: 380.1978. 
 
Representative procedure for removal of PMB group and simultaneous aromatization of 
fused dihydropyrazoles 10a, 10b, 10j and 15a−d: synthesis of methyl 3-isopropyl-1,4-
dihydropyrazolo[4,3-b]indole-1-carboxylate (11a). The mixture of 10a (60 mg, 0.16 mmol) and 
CAN (175 mg, 0.32 mmol) in MeCN (1.8 cm3) and H2O (0.2 cm3) was stirred at room temperature 
for 12 h. The resulting mixture was diluted with H2O and extracted with EtOAc twice. The combined 
extracts were washed with brine, dried over Na2SO4 and concentrated in vacuo. The residue was 
chromatographed on silica gel (hexane/EtOAc = 3/1) to afford the title compound 11a (36 mg, 87%) 
as a white solid: mp 183 °C; IR (neat): νmax/cm-1  1742 (C=O); δH (500 MHz, CDCl3) 1.46 (6H, d, J 
6.9 Hz), 3.28−3.35 (1H, m), 4.16 (3H, s), 7.21−7.25 (1H, m), 7.34−7.44 (2H, m), 7.95−8.00 (1H, m), 
8.28 (1H, br s); δC (125 MHz, CDCl3) 21.7 (2C), 27.9, 54.6, 112.3, 114.5, 120.2, 121.6, 125.4, 129.5, 
133.1, 143.5, 147.5, 150.7; HRMS (FAB+) Calcd for C14H16N3O2 [M+H]+: 258.1243, found: 
258.1238. 
 
Methyl 2-(4-methoxybenzyl)-2-(prop-2-ynyl)hydrazinecarboxylate (13). To a stirred 
mixture of hydrazine 8a (105 mg, 0.5 mmol) and K2CO3 (138 mg, 1 mmol) in DMF (1 cm3) was 
added propargyl bromide (0.045 cm3, 0.6 mmol) and the resulting mixture was stirred at 40 °C for 12 
h. After being cooled to room temperature, the mixture was diluted with H2O and extracted with 
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EtOAc twice. The combined extracts were washed with brine, dried over Na2SO4 and concentrated in 
vacuo. The residue was chromatographed on silica gel (hexane/EtOAc = 4/1) followed by 
recrystallization from EtOAc–hexane to afford the title compound 13 (105 mg, 85%) as colourless 
crystals: mp 71 °C; IR (neat): νmax/cm-1 3227 (C≡CH), 1714 (C=O); δH (500 MHz, CDCl3) 2.37 (1H, 
t, J 2.3 Hz), 3.59 (2H, br s), 3.66 (3H, s), 3.79 (3H, s), 3.86 (2H, br s), 5.99 (1H, br s), 6.85 (2H, d, J 
8.6 Hz), 7.30 (2H, d, J 8.6 Hz); δC (125 MHz, CDCl3) 45.3, 52.3, 55.1, 59.6, 61.4, 74.9, 113.7 (2C), 




methoxybenzyl)hydrazinecarboxylate (14). Under argon atmosphere, the mixture of iodobenzene 
12 (103 mg, 0.33 mmol), propargyl hydrazine 13 (97 mg, 0.39 mmol), Pd(PPh3)2Cl2 (11 mg, 0.016 
mmol), CuI (3.1 mg, 0.016 mmol) and Et3N (0.23 cm3, 1.63 mmol) in THF (2 cm3) was stirred at 
40 °C for 5 h. After being cooled to room temperature, the mixture was filtered through Celite and 
the filtrate was concentrated in vacuo. The residue was chromatographed on silica gel 
(hexane/EtOAc = 3/1) to afford the title compound 14 (100 mg, 70%) as a brown oil: IR 
(neat): νmax/cm-1 2251 (C≡C), 2115 (N3), 1718 (C=O); δH (500 MHz, CDCl3) 1.42 (3H, t, J 7.2 Hz), 
3.68 (3H, s), 3.79 (3H, s), 3.86 (2H, s), 3.97 (2H, br s), 4.41 (2H, q, J 7.2 Hz), 6.40 (1H, br s), 6.87 
(2H, d, J 8.6 Hz), 7.35 (2H, d, J 8.6 Hz), 7.48 (1H, d, J 8.0 Hz), 7.76−7.78 (1H, m), 7.83 (1H, s); δC 
(125 MHz, CDCl3) 14.2, 46.3, 52.3, 55.2, 60.1, 61.6, 82.3, 91.4, 113.8 (2C), 118.7, 119.2, 125.5, 
127.8, 130.7 (2C), 131.5, 133.1, 141.9, 155.8, 159.3, 165.1; HRMS (FAB+) Calcd for C22H24N5O5 
[M+H]+: 438.1777, found: 438.1781. 
 
Methyl 5-[2-azido-4-(ethoxycarbonyl)phenyl]-2-(4-methoxybenzyl)-2,3-dihydro-1H-
pyrazole-1-carboxylate (9k). Under argon atmosphere, the mixture of 14 (95 mg, 0.22 mmol), 
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IPrAuCl (4.3 mg, 0.007 mmol) and AgOTf (1.8 mg, 0.007 mmol) in 1,2-dichloroethane (1 cm3) was 
stirred at 50 °C for 4 h. After being cooled to room temperature, the mixture was filtered through 
Celite and the filtrate was concentrated in vacuo. The residue was chromatographed on silica gel 
(hexane/EtOAc = 3/1) to afford the title compound 9k (70 mg, 74%) as a yellow oil: IR 
(neat): νmax/cm-1 2114 (N3), 1714 (C=O); δH (500 MHz, CDCl3) 1.40 (3H, t, J 7.2 Hz), 3.59 (3H, s), 
3.80−3.82 (5H, m), 3.95 (2H, br s), 4.40 (2H, q, J 7.2 Hz), 5.67 (1H, t, J 2.3 Hz), 6.89 (2H, d, J 9.2 
Hz), 7.37−7.39 (3H, m), 7.78−7.80 (1H, m), 7.86 (1H, s); δC (125 MHz, CDCl3) 14.3, 52.9, 55.2, 
57.3, 61.3, 61.5, 112.6, 113.6 (2C), 119.5, 125.4, 128.3, 128.5, 130.0, 131.2 (2C), 131.4, 136.7, 137.9, 
155.0, 159.2, 165.4; HRMS (FAB+) Calcd for C22H24N5O5 [M+H]+: 438.1778, found: 438.1776.  
 
6-Ethyl 1-methyl 2-(4-methoxybenzyl)-1,2,3,4-tetrahydropyrazolo[4,3-b]indole-1,6-
dicarboxylate (10j). Under argon atmosphere, a solution of 9k (350 mg, 0.8 mmol) in o-
dichlorobenzene (8 cm3) was stirred at 150 °C for 2 h. After being cooled to room temperature, the 
resulting mixture was chromatographed on silica gel (hexane/EtOAc = 2/1) to afford the title 
compound 10j (141 mg, 43%) as a brown solid: mp 152 °C; IR (neat): νmax/cm-1 1708 (C=O); δH 
(500 MHz, CDCl3) 1.41 (3H, t, J 7.2 Hz), 3.78 (3H, s), 3.87 (3H, s), 4.07 (2H, s), 4.23 (2H, br s), 
4.39 (2H, q, J 7.2 Hz), 6.84 (2H, d, J 8.6 Hz), 7.32 (2H, d, J 8.6 Hz), 7.82−7.85 (2H, m), 8.06 (1H, s), 
8.52 (1H, s); δC (125 MHz, CDCl3) 14.4, 52.5, 53.2, 55.2, 60.8, 62.7, 113.8 (2C), 114.3, 118.9, 120.0, 
121.1, 121.4, 123.6, 128.1, 131.0 (2C), 131.6, 139.5, 154.6, 159.3, 167.6; HRMS (FAB+) Calcd for 
C22H24N3O5 [M+H]+: 410.1716, found: 410.1711.  
 
Representative procedure for N-alkylation or N-arylation of 10b, 10j and 10g: synthesis of 
6-ethyl 1-methyl 4-benzyl-3-isopropyl-2-(4-methoxybenzyl)-1,2,3,4-tetrahydropyrazolo[4,3-
b]indole-1,6-dicarboxylate (15c). To a solution of 10b (39 mg, 0.09 mmol) in DMF (1 cm3) was 
added NaH (2.6 mg, 0.11 mmol) at room temperature. After being stirred for 30 min, BnBr (0.012 
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cm3, 0.11 mmol) was added dropwise and then the mixture was stirred for further 30 min. The 
resulting mixture was diluted with H2O and extracted with EtOAc twice. The combined extracts were 
washed with brine, dried over Na2SO4 and concentrated in vacuo. The residue was chromatographed 
on silica gel (hexane/EtOAc = 5/1) to afford the title compound 15c (44 mg, 90%) as a yellow oil: IR 
(neat): νmax/cm-1 1701 (C=O); δH (500 MHz, CDCl3) 0.60−0.64 (6H, m), 1.40 (3H, t, J 7.1 Hz), 
1.57−1.63 (1H, m), 3.58 (1H, d, J 3.4 Hz), 3.63 (1H, d, J 12.0 Hz), 3.78 (3H, s), 3.89 (3H, s), 4.08 
(1H, d, J 12.0 Hz), 4.38 (2H, q, J 7.1 Hz), 5.11 (1H, d, J 16.0 Hz), 5.45 (1H, d, J 16.0 Hz), 6.77 (2H, 
d, J 8.6 Hz), 6.96−6.98 (2H, m), 7.10 (2H, d, J 8.6 Hz), 7.31−7.32 (3H, m), 7.83−7.85 (2H, m), 8.04 
(1H, s); δC (125 MHz, CDCl3) 14.4, 16.6, 19.1, 32.8, 48.4, 53.0, 55.2, 60.7, 62.2, 68.2, 112.5, 113.3 
(2C), 119.2, 119.8, 121.0, 123.3, 126.6 (2C), 128.0, 128.1, 128.9 (2C), 131.7 (2C), 136.6, 136.7, 
139.4, 140.1, 159.1, 167.5, 169.9; HRMS (FAB+) Calcd for C32H36N3O5 [M+H]+: 542.2655, found: 
542.2661.  
 
Representative procedure for hydrolysis of the methyl carbamate and ester of 11b and 
11d−i: synthesis of 1,4-dihydropyrazolo[4,3-b]indole-6-carboxylic acid (5a). To a mixture of 11d 
(40 mg, 0.14 mmol) in THF (1 cm3), H2O (0.5 cm3) and MeOH (0.5 cm3) was added 3N NaOH (0.2 
cm3) and the mixture was stirred at 60 °C for 5 h. After being cooled to room temperature, the 
mixture was neutralized with 3N HCl (0.2 cm3). The resulting mixture was chromatographed on 
silica gel (CHCl3/MeOH = 9/1) to afford the title compound 5a (22 mg, 78%) as a white solid: mp 
>300 °C; IR (neat): νmax/cm-1 1726 (C=O); δH (500 MHz, DMSO-d6) 7.64 (1H, s), 7.68 (1H, d, J 8.4 
Hz), 7.83 (1H, d, J 8.4 Hz), 8.03 (1H, s), 10.65 (1H, s), 12.30−13.32 (2H, m); δC (125 MHz, DMSO-
d6) 113.7, 114.7, 116.9, 118.5, 119.0, 126.0, 132.3, 136.5, 144.1, 168.0; HRMS (FAB+) Calcd for 
C10H8N3O2 [M+H]+: 202.0617, found: 202.0612; tR (method A): 14.31 min.  
 
CK2 kinase assay 
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CK2 inhibitory activities were evaluated by the off-chip mobility shift assay by the 
QuickScout® service from Carna Bioscience (Kobe, Japan). Human GST-fusion CK2α(1-391) or 
CK2α’(1-350) was co-expressed with His-tagged human CK2β(1-215) using baculovirus expression 
system. GST-CK2α1 was purified by using glutathione sepharose chromatography. Each chemical in 
DMSO at different concentrations was diluted fourfold with reaction buffer [20 mM HEPES (pH 7.5), 
0.01% Triton X-100, 2 mM DTT]. For CK2 reactions, a combination of the compound, 1 µM 
CK2tide, 5 mM MgCl2, 5 µM ATP in reaction buffer (0.020 cm3) were incubated with each CK2 in 
PP 384-well plates at room temperature for 1 h (n = 2). The reaction was terminated by addition of 
0.060 cm3 of termination buffer (Carna Biosciences). Substrate and product were separated by 
electrophoretic means using the LabChip3000 system. The kinase reaction was evaluated by the 
product ratio, which was calculated from the peak heights of the substrate (S) and product (P): 
[P/(P+S)]. Inhibition data were calculated by comparing with no-enzyme controls for 100% 
inhibition and no-inhibitor reactions for 0% inhibition. IC50 values were calculated using GraphPad 
Prism 5 software (GraphPad Software, Incorporated, La Jolla, CA, USA). 
 
Acknowledgements 
This work was supported by Fundamental Studies in Health Sciences of the National Institute 
of Biomedical Innovation (NIBIO), and Grants-in-Aid for Scientific Research and Platform for Drug 
Discovery, Informatics, and Structural Life Science from the MEXT, Japan. Z.H. and Y.S. are 
supported by the Kobayashi International Scholarship Foundation and by a JSPS Research 
Fellowship for Young Scientists, respectively. 
 
References and notes 
1. (a) L. A. Pinna, Acc. Chem. Res., 2003, 36, 378–384; (b) F. Meggio and L. A. Pinna, FASEB J., 
2003, 17, 349–368. 
13 
 
2. D. W. Litchfield, Biochem. J., 2003, 369, 1–15. 
3. B. Guerra, S. Siemer, B. Boldyreff and O.-G. Issinger, FEBS Lett., 1999, 462, 353–357. 
4. (a) G. M. Unger, A. T. Davis, J. W. Slaton and K. Ahmed, Curr. Cancer Drug Targets, 2004, 4, 
77–84; (b) K. A. Ahmad, G. Wang, G. Unger, J. Slaton and K. Ahmed, Adv. Enzyme Regul., 
2008, 48, 179–187; (c) P. P. Scaglioni, T. M. Yung, L. F. Cai, H. Erdjument-Bromage, A. J. 
Kaufman, B. Singh, J. Teruya-Feldstein, P. Tempst and P. P. Pandolfi, Cell, 2006, 126, 269–
283; (d) F. A. Piazza, M. Ruzzene, C. Gurrieri, B. Montini, L. Bonanni, G. Chioetto, G. Di 
Maira, F. Barbon, A. Cabrelle, R. Zambello, F. Adami, L. Trentin, L. A. Pinna and G. 
Semenzato, Blood, 2006, 108, 1698–1707; (e) S. Mishra, V. Pertz, B. Zhang, P. Kaur, H. 
Shimada, J. Groffen, Z. Kazimierczuk, L. A. Pinna and N. Heisterkamp, Leukemia, 2007, 21, 
178–180. 
5. (a) J. W. Critchfield, J. E. Coligan, T. M. Folks and S. T. Butera, Proc. Natl. Acad. Sci. U. S. A., 
1997, 94, 6110–6115; (b) S. Sarno, S. Moro, F. Meggio, G. Zagotto, D. Dal Ben, P. Ghisellini, 
R. Battistutta, G. Zanotti and L. A. Pinna, Pharmacol Ther., 2002, 93, 159–168; (c) H. L. Yim, 
Y. H. Lee, C. H. Lee and S. K. Lee, Planta Med., 1999, 65, 9–13; (d) R. Szyszka, N. 
Grankowski, K. Felczak and D. Shugar, Biochem. Biophys. Res. Commun., 1995, 208, 418–
424; (e) E. Vangrevelinghe, K. Zimmermann, J. Schoepfer, R. Portmann, D. Fabbro and P. 
Furet, J. Med. Chem., 2003, 46, 2656–2662; (f) Z. Nie, C. Perretta, P. Erickson, S. Margosiak, 
R. Almassy, J. Lu, A. Averill, K. M. Yager and S. Chu, Bioorg. Med. Chem. Lett., 2007, 17, 
4191–4195; (g) F. Pierre, P. C. Chua, S. E. O’Brien, A. Siddiqui-Jain, P. Bourbon, M. Haddach, 
J. Michaux, J. Nagasawa, M. K. Schwaebe, E. Stefan, A. Vialettes, J. P. Whitten, K. T. Chen, L. 
Darjania, R. Stansfield, K. Anderes, J. Bliesath, D. Drygin, C. Ho, M. Omori, C. Proffitt, N. 
Streiner, K. Trent, W. G. Rice and D. M. Ryckman, J. Med. Chem., 2011, 54, 635–654; (h) R. 
Battistutta, G. Cozza, F. Pierre, E. Papinutto, G. Lolli, S. Sarno, S. E. O’Brien, A. Siddiqui-Jain, 
M. Haddach, K. Anderes, D. M. Ryckman, F. Meggio and L. A. Pinna, Biochemistry, 2011, 50, 
14 
 
8478–8488; (i) R. Prudent and C. Cochet, Chem. Biol., 2009, 16, 112–120. 
6 (a) Y. Suzuki, J. Cluzeau, T. Hara, A. Hirasawa, G. Tsujimoto, S. Oishi, H. Ohno and N. Fujii, 
Arch. Pharm., 2008, 341, 554–561; for the initial report of pyrazine-based CK2 inhibitors, see: 
(b) N. Fuchi, Y. Iura, H. Kaneko, M. Yamada and Y. Sekitani, Jpn. Pat., 145786, 2007; (c) N. 
Fuchi, Y. Iura, H. Kaneko, A. Nitta, K. Suyama, H. Ueda, S. Yamaguchi, K. Nishimura, S. Fujii, 
Y. Sekiya, M. Yamada, T. Takahashi, Bioorg. Med. Chem. Lett., 2012, 22, 4358–4361. 
7. (a) T. Nakaniwa, T. Kinoshita, Y. Sekiguchi, T. Tada, I. Nakanishi, K. Kitaura, Y. Suzuki, H. 
Ohno, A. Hirasawa and G. Tsujimoto, Acta Crystallogr. Sect. F, 2009, 65, 75–79; (b) T. 
Kinoshita, Y. Sekiguchi, H. Fukada, T. Nakaniwa, T. Tada, S. Nakamura, K. Kitaura, H. Ohno, 
Y. Suzuki, A. Hirasawa, I. Nakanishi and G. Tsujimoto, Mol. Cell. Biochem., 2011, 356, 97–
105. 
8. Z. Hou, I. Nakanishi, T. Kinoshita, M. Yasue, R. Misu, Y. Suzuki, S. Nakamura, T. Kure, H. 
Ohno, K. Murata, K. Kitaura, A. Hirasawa, G. Tsujimoto, S. Oishi and N. Fujii, J. Med. Chem., 
2012, 55, 2899–2903. 
9. Y. Suzuki, S. Oishi, Y. Takei, M. Yasue, R. Misu, S. Naoe, Z. Hou, T. Kure, I. Nakanishi, H. 
Ohno, A. Hirasawa, G. Tsujimoto and N. Fujii, Org. Biomol. Chem., 2012, 10, 4907–4915. 
10. Lopez et al. have determined the tautomeric structures of various pyrazoles and indazoles by 
13C NMR analysis, see: C. Lopez, R. M. Claramunt, A. Trofimenko and J. Elguero, Can. J. 
Chem., 1993, 71, 678–684. 
11. (a) K. Bougrin and M. Soufiaoui, Tetrahedron Lett., 1995, 36, 4065–4068; (b) K. J. Doyle, P. 
Rafferty, R. W. Steele, D. J. Wilkins, M. Hockley, L. P. Arnold and A. M. Ericsson, WO Pat., 
WO 027822, 2000; (c) A. Mandour, E. EI-Sawy, K. Shaker and M. Mustafa, Acta Pharm., 
2010, 60, 73–88. 
12. For reviews, see: (a) B. Ganem, Acc. Chem. Res., 2009, 42, 463–472; (b) L. A. Wessjohann, D. 
G. Rivera and O. E. Vercillo, Chem. Rev., 2009, 109, 796–814. 
15 
 
13. Y. Suzuki, S. Naoe, S. Oishi, N. Fujii and H. Ohno, Org. Lett., 2012, 14, 326–329. 
14. For related intramolecular C-H amination reactions using transition metal complexs, see: (a) S. 
Cenini, E. Gallo, A. Penoni, F. Ragaini and S. Tollari, Chem. Commun., 2000, 2265–2266; (b) 
B. J. Stokes, H. Dong, B. E. Leslie, A. L. Pumphrey and T. G. Driver, J. Am. Chem. Soc., 2007, 
129, 7500–7501; (c) M. Shen, B. E. Leslie and T. G. Driver, Angew. Chem. Int. Ed., 2008, 47, 
5056–5059; (d) H. Dong, M. Shen, J. E. Redford, B. J. Stokes, A. L. Pumphrey and T. G. 
Driver, Org. Lett., 2007, 25, 5191–5194; (e) W. Shou, L. Juan, G. Tongxun, L. Zhenyang and J. 
Guochen, Organometallics, 2009, 28, 6847–6854; (f) H. Dong, R. T. Latka and T. G. Driver, 
Org. Lett., 2012, 13, 2727–2729; for related reactions using Lewis acids, see: (g) H. Takeuchi,  
M. Maeda, M. Mitani and K. Koyama, J. Chem. Soc., Perkin Trans. 1, 1987, 57–60; (h) P. 
Spagnolo and P. Zanirato, J. Chem. Soc., Perkin Trans. 1, 1988, 2615–2620; for related 
thermal reactions, see: (i) R. B. Miller, S. Dugar and J. R. Epperson, Heterocycles, 1987, 25, 
217–220; (j) M. Pudloa, D. Csányib, F. Moreaua, G. Hajósb, Z. Riedlb and J. Sapi, 
Tetrahedron, 2007, 63, 10320–10329. 
15. The reaction with 5 mol% of IPrAuNTf2 prepared from IPrAuCl and AgNTf2 proceeded 
smoothly to afford the dihydropyrazole 9a in slightly lower yield (65%). As we previously 
reported,13 the use of silver salts alone is nonreactive for the three-component annulation. 
These results supported that the in situ generated active gold(I) species (IPrAuOTf or 
IPrAuNTf2) is the real catalyst. 
16. The 3-chloroaniline moiety of CX-4945, which locates at the similar position with that of R1 or 
R2 in pyrazolo[4,3-b]indoles 5, has been suggested to fit well within a small hydrophobic 
































4a: R = 2-thienyl
4b: R = 4-methoxyphenyl  





































































Figure 3. Phenylpyrazole-based CK2 inhibitor 3, benzo[g]indazoles 4, pyrazolo[4,3-b]indoles 5 and 
















































































































Scheme 3. Model experiments.  
Reagents and conditions: (a) IPrAuCl/AgOTf (3 mol%), 1,2-DCE, 50 °C, 4 h, 73%; (b) RuCl3·nH2O 


















































































































































































































































































a Isolated yields. b IPrAuCl/AgNTf2 (3 mol%) were used as the catalyst. c The reaction was carried 
out at rt. d Cyclohexanone was used instead of an aldehyde. e The reaction was carried out in the 































Scheme 4. Synthesis of the dihydropyrazole 9k and dihydropyrazolo[4,3-b]indole 10j. 
Reagents and conditions: (a) PdCl2(PPh3)2/CuI (5 mol%), Et3N, THF, 40 °C, 5 h, 70%; (b) 











































































































































Scheme 5. Synthesis of CK2 inhibitor compounds 5a−g.  
Reagents and conditions: (a) CAN, MeCN/H2O, rt; (b) NaH, BnBr, DMF, rt; (c) NaH, 1-fluoro-4-





















Compd R1 R2 
IC50 [µM]a 
CK2α CK2α' 
5a H H 0.785 0.652 
5b i-Pr H > 1.00 > 1.00 
5c Ph H 0.0583 0.0280 
5d H Bn > 1.00 ~ 1.00 
5e H 4-NO2Ph 0.0581 0.0280 
5f i-Pr Bn > 1.00 > 1.00 














a Inhibition values were determined by the CK2 kinase assay 
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